Kacheva S, Kolk K, Morgenthaler NG, Brabant G, Karges W
Yaimi May 28, 2025 Excelente
Patients with T2DM, persons at risk for AD, had a significantly lower associated risk of AD after administered exenatide, liraglutide and dulaglutide ( Conclusion Increasing evidence suggests that anti-diabetes medicine, GLP-1R agonists, have multiple neuroprotective mechanisms in AD models, such as anti-inflammation, anti-oxidative stress, reducing A aggregation/deposition and tau protein hyperphosphorylation, reducing neuronal apoptosis and neurotoxicity, increasing cell proliferation and neurogenesis, increasing synaptic plasticity, and other beneficial effects
Be sure to complete the form with as much information as initially possible.
Latin American consensus on hypertension in patients with diabetes type 2 and metabolic syndrome
Alterations of the thalamo-cortical system in rats prenatally exposed to ethanol are prevented by concurrent administration of acetyl-L-carnitine Brain Res 1995